Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -202620252024202320222021202020192018201720162015 12 March 2019 Biocartis and Bristol Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies Non-regulated information 28 February 2019 Biocartis announces CE-IVD marking of its Idylla™ MSI Test Non-regulated information 26 February 2019 Biocartis Places Its 1,000th Idylla™ Instrument with Geisinger in US Non-regulated information 7 January 2019 Biocartis and Nichirei Bioscience Announce Commercialization Collaboration for Japanese Market Non-regulated information 3 December 2018 Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test Non-regulated information 29 November 2018 Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Non-regulated information 1 November 2018 Eight Idylla™ Performance Studies to be Presented at the Association for Molecular Pathology Conference in the US Non-regulated information 19 October 2018 Studies on Idylla™ MSI and RAS liquid biopsy tests to be presented at ESMO congress Non-regulated information 28 August 2018 Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy Non-regulated information 31 July 2018 Study Abstract on Performance of Idylla™ RAS tests Selected for Oral Presentation at 70th AACC Annual Scientific Meeting in Chicago, IL (US) Non-regulated information Pagination First page « First Previous page ‹‹ … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page ›› Last page Last »